Erytech Pharma SA bags US$57m from SQZ Biotechnologies
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (141m).
GM proponents grill German government
German GM proponents have taken action against discrimination of food products generated by gene editing.
New CEO for Valo Therapeutics
Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the companys inception in 2017.
IL-10R-deficient macrophages trigger IBD
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Machine learning for high-content analysis: User stories
Scientists from the University of Washington are using the Phenoglyphs machine learning module to achieve faster high-content analysis through automation and simplification.
Breakthrough in liquid biopsy
German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Evotec bags US$23.8m to fight tuberculosis
The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.